Gilles Lambert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/302306/publications.pdf

Version: 2024-02-01

50 papers	2,057 citations	279701 23 h-index	243529 44 g-index
51 all docs	51 docs citations	51 times ranked	2357 citing authors

#	Article	IF	Citations
1	The PCSK9 decade. Journal of Lipid Research, 2012, 53, 2515-2524.	2.0	355
2	Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. Journal of Biological Chemistry, 2006, 281, 6211-6218.	1.6	260
3	Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor. Endocrinology, 2006, 147, 4985-4995.	1.4	105
4	PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35.	2.0	99
5	Inhibiting PCSK9 â€" biology beyond LDL control. Nature Reviews Endocrinology, 2019, 15, 52-62.	4.3	96
6	PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) ExÂVivo. JACC Basic To Translational Science, 2016, 1, 419-427.	1.9	94
7	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831.	5.1	90
8	Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 2008, 196, 659-666.	0.4	81
9	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 592-598.	1.1	77
10	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	1.2	57
11	PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis, 2016, 254, 249-253.	0.4	54
12	Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2042-2047.	1.1	48
13	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
14	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	0.6	44
15	PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. Clinical Science, 2018, 132, 1075-1083.	1.8	39
16	The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Clinical Science, 2017, 131, 261-268.	1.8	34
17	Lipoprotein metabolism in familial hypercholesterolemia. Journal of Lipid Research, 2021, 62, 100062.	2.0	31
18	Normalization of Low-Density Lipoprotein Receptor Expression inÂReceptor Defective Homozygous Familial Hypercholesterolemia byÂInhibition of PCSK9 With Alirocumab. Journal of the American College of Cardiology, 2014, 64, 2299-2300.	1.2	30

#	Article	IF	Citations
19	Characterization of the First PCSK9 Gain of Function Homozygote. Journal of the American College of Cardiology, 2015, 66, 2152-2154.	1.2	30
20	PCSK9: a promising therapeutic target for dyslipidemias?. Trends in Endocrinology and Metabolism, 2006, 17, 79-81.	3.1	28
21	A hemorrhagic transformation model of mechanical stroke therapy with acute hyperglycemia in mice. Journal of Comparative Neurology, 2018, 526, 1006-1016.	0.9	28
22	VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 819-829.	1.1	27
23	Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis, 2022, 349, 82-91.	0.4	26
24	Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. Journal of Lipid Research, 2018, 59, 892-900.	2.0	25
25	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	1.1	23
26	A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. Journal of Lipid Research, 2020, 61, 1128-1139.	2.0	22
27	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. Atherosclerosis, 2020, 293, 49-56.	0.4	21
28	Lipoprotein(a) Cellular Uptake ExÂVivo and Hepatic Capture InÂVivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC Basic To Translational Science, 2020, 5, 549-557.	1.9	21
29	The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. Cardiovascular Research, 2022, 118, 2103-2111.	1.8	20
30	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis, 2021, 326, 47-55.	0.4	18
31	Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation. Stroke, 2014, 45, 3086-3088.	1.0	14
32	Stable Isotope Kinetic Study of ApoM (Apolipoprotein M). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 255-261.	1.1	14
33	PCSK9 inhibitors. Swiss Medical Weekly, 2015, 145, w14094.	0.8	13
34	Plasma PCSK9 measurement by liquid chromatographyâ€"Tandem mass spectrometry and comparison with conventional ELISA. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 24-29.	1.2	10
35	Key aspects of PCSK9 inhibition beyond LDL lowering. Current Opinion in Lipidology, 2018, 29, 453-458.	1.2	10
36	Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovascular Diabetology, 2022, 21, 21.	2.7	10

#	Article	IF	Citations
37	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. International Journal of Molecular Sciences, 2021, 22, 13602.	1.8	10
38	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©rosclÃ©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	0.7	9
39	PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 880-885.	1.1	6
40	Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic To Translational Science, 2019, 4, 425-427.	1.9	5
41	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	1.1	5
42	Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003489.	1.6	5
43	Heart to heart with PCSK9. European Heart Journal, 2021, 42, 3091-3093.	1.0	4
44	Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. Journal of Clinical Lipidology, 2017, 11, 289-293.	0.6	3
45	Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study. Frontiers in Genetics, 2021, 12, 728526.	1.1	3
46	PCSK9 inhibition for autosomal recessive hypercholesterolemia. Atherosclerosis, 2019, 284, 209-211.	0.4	2
47	Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report. European Heart Journal - Case Reports, 2019, 3, ytz019.	0.3	2
48	Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms. Current Atherosclerosis Reports, 2022, , 1.	2.0	2
49	Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 101161ATVBAHA122315499.	1.1	2
50	PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Hyperglycemic Mice Increases the Risk of Hemorrhagic Transformation of Ischemic Stroke. Stroke, 2021, 52, e545-e547.	1.0	1